Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Diclegis delayed-release tablets for NVP treatment now eligible for Medicaid coverage

Duchesnay USA today announced that Diclegis (doxylamine succinate 10mg, pyridoxine hydrochloride 10mg) delayed-release tablets for the treatment of nausea and vomiting of pregnancy, more commonly known as morning sickness, is now available for coverage under the state and federal Medicaid program effective July 1st, 2013.

9 Jul 2013

El Lilly calls for Medicare coverage of beta-amyloid imaging agents for Alzheimer's disease

Eli Lilly and Company today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a draft decision proposing Coverage with Evidence Development for the use of beta-amyloid positron emission tomography (PET) imaging agents. Beta-amyloid imaging agents are used to evaluate patients with cognitive impairment for Alzheimer's Disease and other causes of cognitive decline.

5 Jul 2013

New endoscopic technique reduces symptoms in gastroparesis patients

Physicians at Johns Hopkins say they are encouraged by early results in three patients of their new treatment for gastroparesis, a condition marked by the failure of the stomach to properly empty its contents into the small intestine.

5 Jul 2013

Genentech's Perjeta regimen gets FDA Priority Review for HER2-positive early stage breast cancer

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.

2 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

Brisdelle receives FDA approval to treat hot flashes associated with menopause

The U.S. Food and Drug Administration today approved Brisdelle (paroxetine) to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only non-hormonal treatment for hot flashes approved by the FDA.

29 Jun 2013

People receiving emergency gallbladder surgery are more likely to experience complications

If you have severe pain just below the right side of your rib cage, you may have a gallbladder problem. And it is typically better to seek medical attention sooner than later.

28 Jun 2013

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.

28 Jun 2013

FDA approves Novartis' Exelon Patch for treatment of severe Alzheimer's disease

The US Food and Drug Administration has expanded the approved indication for Exelon Patch (rivastigmine transdermal system) to include the treatment of people with severe Alzheimer's disease with Exelon Patch 13.3mg/24h.

28 Jun 2013

Study: More people are being affected by drug-induced liver injury than ever before

More people are being affected by drug-induced liver injury (DILI) than ever before, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

27 Jun 2013

Stimulation of P6 antiemetic point with acupressure wristbands reduces migraine nausea

Nausea is one of the most debilitating symptoms of migraine and affects 80 percent of migraine suffers in the United States. Leading headache physician, Dr. Zoltan Medgyessy of the Berolina Clinic in Lohne, Germany demonstrated in a trial that pressure to the P6 antiemetic point on the inner wrist with an acupressure wristband is an effective and quick therapy for relieving nausea of migraine sufferers.

27 Jun 2013

Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women

Sprout Pharmaceuticals, the Raleigh-based pharmaceutical company developing flibanserin, a treatment being evaluated for Hypoactive Sexual Desire Disorder in pre-menopausal women, confirmed today that the company has resubmitted the New Drug Application for flibanserin earlier this year and expects US Food and Drug Agency action before the end of 2013.

27 Jun 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Excessive intake of cola and honey can cause fainting and arrhythmia symptoms, shows study

Drinking excessive amounts of cola and eating honey made from the pollen of Rhododendrons can cause unusual syncope (fainting) and symptoms of arrhythmia, report two case studies presented as abstracts at the EHRA EUROPACE 2013 meeting, in Athens 23 to 26 June.

25 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

FDA approves use of Plan B One-Step pill for all women with child-bearing potential

Today, the U.S. Food and Drug Administration announced it has approved the use of Plan B One-Step (levonorgestrel) as a nonprescription product for all women of child-bearing potential.

21 Jun 2013

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

20 Jun 2013

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.

19 Jun 2013

Women with polycystic ovary syndrome lose more weight when they take two drugs

Women with polycystic ovary syndrome, or PCOS, lost significantly more weight when they took two drugs that are traditionally used to treat diabetes, rather than either drug alone, a study from Slovenia demonstrates. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

Certain gastrointestinal types of GVHD are associated with worsened quality of life and death

Joseph Pidala, M.D., M.S., assistant member of the Blood and Bone Marrow Transplant and Immunology programs at Moffitt Cancer Center, and colleagues from the Chronic Graft-Versus-Host Disease Consortium have determined that certain gastrointestinal and liver-related types of chronic graft-versus-host disease (GVHD) are associated with worsened quality of life and death.

18 Jun 2013

Nausea News and Research

Further Reading

Diclegis delayed-release tablets for NVP treatment now eligible for Medicaid coverage

El Lilly calls for Medicare coverage of beta-amyloid imaging agents for Alzheimer's disease

New endoscopic technique reduces symptoms in gastroparesis patients

Genentech's Perjeta regimen gets FDA Priority Review for HER2-positive early stage breast cancer

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Brisdelle receives FDA approval to treat hot flashes associated with menopause

People receiving emergency gallbladder surgery are more likely to experience complications

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

FDA approves Novartis' Exelon Patch for treatment of severe Alzheimer's disease

Study: More people are being affected by drug-induced liver injury than ever before

Stimulation of P6 antiemetic point with acupressure wristbands reduces migraine nausea

Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women

Eisai submits BELVIQ NDS with Health Canada

Excessive intake of cola and honey can cause fainting and arrhythmia symptoms, shows study

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

FDA approves use of Plan B One-Step pill for all women with child-bearing potential

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Women with polycystic ovary syndrome lose more weight when they take two drugs

Certain gastrointestinal types of GVHD are associated with worsened quality of life and death

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News